Axovant Sciences (NASDAQ:AXON) Stock Rating Reaffirmed by Cowen

Share on StockTwits

Cowen reissued their hold rating on shares of Axovant Sciences (NASDAQ:AXON) in a research report report published on Thursday, September 20th.

Several other research firms have also recently weighed in on AXON. Oppenheimer reissued a hold rating on shares of Axovant Sciences in a research note on Wednesday, June 6th. HC Wainwright reaffirmed a buy rating on shares of Axovant Sciences in a research report on Thursday, June 7th. BidaskClub raised shares of Axovant Sciences from a strong sell rating to a sell rating in a research report on Saturday, September 1st. Zacks Investment Research raised shares of Axovant Sciences from a hold rating to a strong-buy rating and set a $5.50 price objective for the company in a research report on Monday, June 11th. Finally, Chardan Capital reaffirmed a hold rating and set a $4.00 price objective on shares of Axovant Sciences in a research report on Wednesday, June 6th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $4.85.

Shares of NASDAQ:AXON traded up $0.19 during midday trading on Thursday, hitting $2.34. The stock had a trading volume of 1,350,191 shares, compared to its average volume of 2,744,320. Axovant Sciences has a 12 month low of $1.02 and a 12 month high of $6.59. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.48. The stock has a market capitalization of $295.44 million, a PE ratio of -1.14 and a beta of -0.01.

Axovant Sciences (NASDAQ:AXON) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.33). On average, equities analysts predict that Axovant Sciences will post -1.67 earnings per share for the current fiscal year.

In related news, Director George Bickerstaff acquired 25,000 shares of Axovant Sciences stock in a transaction on Thursday, August 9th. The stock was purchased at an average cost of $2.07 per share, with a total value of $51,750.00. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $103,500. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 6.00% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its holdings in shares of Axovant Sciences by 1,627.0% during the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock worth $141,000 after buying an additional 58,541 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Axovant Sciences by 3.4% during the first quarter. BlackRock Inc. now owns 3,012,515 shares of the biotechnology company’s stock worth $4,006,000 after buying an additional 100,296 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Axovant Sciences during the second quarter worth $338,000. Paloma Partners Management Co acquired a new stake in shares of Axovant Sciences during the second quarter worth $356,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Axovant Sciences by 2,519.0% during the first quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after buying an additional 176,227 shares in the last quarter. 9.38% of the stock is owned by hedge funds and other institutional investors.

About Axovant Sciences

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Featured Story: Fundamental Analysis

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply